SteadyMed Raises $30 Million in Private Placement
SteadyMed prepares to file New Drug Application (NDA) for Trevyent® in Q2 2017
Financing provides capital for Trevyent commercial launch preparation
SAN RAMON, Calif., April 21, 2017 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has entered into a definitive agreement to sell its ordinary shares and warrants to purchase its ordinary shares for aggregate gross proceeds of approximately $30 million in a private placement. The financing was led by Adage Capital Management, OrbiMed, Deerfield Management and Kingdon Capital Management.
- Published: 21 April 2017
- Written by Editor